- JP-listed companies
- Chordia Therapeutics,Inc
- Income statement
Chordia Therapeutics,Inc (190A) Income statement
Market cap
¥11.2B
P/E ratio
-5.6x
Chordia Therapeutics discovers and develops innovative small-molecule cancer drugs that target RNA regulatory stress in cancer cells for pharmaceutical partners.
| 2019/08 | 2020/08 | 2021/08 | 2022/08 | 2023/08 | 2024/08 | 2025/08 | |
| Revenue | - | - | 800 | - | 2,500 | - | - |
| Operating margin (%) | - | - | - | - | - | - | |
| Operating income | - | - | - | -1,844 | 212 | -1,801 | -1,790 |
| Income before tax | -646 | -975 | -525 | -1,777 | 226 | -1,825 | -1,770 |
| Pretax margin (%) | - | - | -65.7 | - | 9 | - | - |
| Provision for income taxes | - | - | - | 2 | 2 | 2 | 2 |
| Effective tax rate (%) | - | - | - | ||||
| Net income | -512 | -977 | -527 | -1,779 | 223 | -1,827 | -1,786 |
| Earnings per share | -4,927.57 | -6,884.75 | -3,016.58 | -39.78 | 3.96 | -31.11 | -26.03 |
| Dividend per share | - | - | - | - | - | - | - |